Gastrointestinal Manifestations

Japanese Journal of Clinical Immunology

Volumn 27, Issue 3, 2004, Pages 145-155

  Takahashi, Hiroki ^a   Ohara, Mikiko ^a   Imai, Kohzoh ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Chronic intestinal pseudoobstruction; Colonic ulcer; Corticosteroid; Gastrointestinal manifestation; Systemic lupus erythematosus

Indexed keywords

EID: 68549137989     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.27.145     Document Type: Article

References (73)

1. th Ed., Lippincott Williams & Wilkins, Philadelphia, pp843–861, 2002.
2. th Ed., Lippincott Williams & Wilkins, Philadelphia, 26: 1235–1246, 1991.
3. th Ed., Lippincott Williams & Wilkins, Philadelphia, 191: 975–978, 1999.
4. th Ed., Lippincott Williams & Wilkins, Philadelphia, 24: 112–124, 2001.
5. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. Am. J. Gastroenterol. 64: 277–285, 1975.
6. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. Am. J. Gastroenterol. 64: 515–518, 1978.
7. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. Systemic lupus erythematosus ischemic colotis. 14: 637–644, 1979.
8. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. Gastroenterol. Endosc. 24: 405–419, 1982.
9. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. SLE. 16: 890–895, 1981.
10. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. SLE. 41: 2369–2372, 1988.
11. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. SLE. 67: 3455–3458, 1990.
12. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. SLE. 2. 14: 321–326, 1991.
13. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. SLE. 26: 1285–1290, 1991.
14. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. SLE. 33: 235–241, 1993.
15. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. SLE. 43: 227–230.
16. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. SLE. 1. 48: 1409–1412, 1994.
17. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. SLE 1. Gastroenterol. Endosc. 36: 397–403, 1994.
18. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. SLE 1. 9: 279–281, 1994.
19. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. SLE 1. 15: 137–141, 1996.
20. Tsuchiya, M., et al.: Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. SLE 1. 38: 523–528, 1998.
21. Teramoto, J., et al.: Systemic lupus erythematosus with a giant rectal ulcer and perforation. Internal Med. 38: 643–649, 1999.
22. Teramoto, J., et al.: Systemic lupus erythematosus with a giant rectal ulcer and perforation. SLE 1. J. Nara Med. Associat. 52: 91–95, 2001.
23. Teramoto, J., et al.: Systemic lupus erythematosus with a giant rectal ulcer and perforation. SLE 1. 35: 342–346, 2002.
24. Yuasa, S., et al.: A case of systemic lupusu erythematosus presenting with rectal ulcers as the initial clinical manifestation of disease. Clin. Exp. Rheumatol. 20: 407–410, 2002.
25. Juvaissas, A., Krrag, G.: Acute gastrointestinal manifestations of systemic lupus erythematosus. Can. J. Surg. 30: 185–188, 1987.
26. Juvaissas, A., Krrag, G.: Acute gastrointestinal manifestations of systemic lupus erythematosus. Can. J. Surg. 1986, p33, 1987.
27. Juvaissas, A., Krrag, G.: Acute gastrointestinal manifestations of systemic lupus erythematosus. Can. J. Surg. 26: 1247–1256, 1991.
28. Juvaissas, A., Krrag, G.: Acute gastrointestinal manifestations of systemic lupus erythematosus. Can. J. Surg. 33: 209–214, 1993.
29. Juvaissas, A., Krrag, G.: Acute gastrointestinal manifestations of systemic lupus erythematosus. Can. J. Surg. 9: 218–224, 1997.
30. Juvaissas, A., Krrag, G.: Acute gastrointestinal manifestations of systemic lupus erythematosus. RA. 21: 460–465, 1999.
31. Sjögren, R.: Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 37: 1265–1282, 1994.
32. Lock, G., et al: Gastrointestinal manifestations of progressive systemic sclerosis. Am. J. Gastroenterol. 92: 763–771, 1997.
33. Lock, G., et al: Gastrointestinal manifestations of progressive systemic sclerosis. Am. J. Gastroenterol. 26: 1223–1233, 1991.
34. Schuffler M.D., et al.: Chronic intestinal pseudo-obstruction. Medicine 60: 173–196, 1981.
35. Verne, G.N., Sninsky, C.A.: Chronic intestinal pseudo-obstruction. Dig. Dis. 13: 163–181, 1995.
36. H.C., Saudah, et al., Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma, N. Engl. J.M., (1991), 325, 1461-1467
37. Perlemuter, G., et al.: Octreotide treatment of chronic intestinal pseudo-obstruction secondary to connective tissue disease. Arthritis Rheum. 42: 1545–1549, 1999.
38. von der Ohe, M. R., et al.: Differential regional effect of octreotide on human gastrointestinal motor function. Gut 36: 743–748, 1995.
39. von der Ohe, M. R., et al.: Differential regional effect of octreotide on human gastrointestinal motor function. Gut 39: 768–773, 1999.
40. von der Ohe, M. R., et al.: Differential regional effect of octreotide on human gastrointestinal motor function. Gut 100: 819–828, 2003.
41. Kagen, L.J., et al.: Cricopharyngeal obstruction in inflammatory myopathy (polymyositis/dermatomyositis). Arthritis Rheum. 28: 630–636, 1985.
42. Kagen, L.J., et al.: Cricopharyngeal obstruction in inflammatory myopathy (polymyositis/dermatomyositis). Arthritis Rheum. 1. 36: 99–104, 1990.
43. Callen, J. P.: Myositis and malignancy. Curr. Opin. Rheumatol. 6: 590–594, 1994.
44. Callen, J. P.: Myositis and malignancy. Curr. Opin. Rheumatol. 27: 499–505, 1985.
45. Callen, J. P.: Myositis and malignancy. Curr. Opin. Rheumatol. 53: 2540–2544, 1995.
46. Jennette, J.C., et al: Nomenclature of systemic vasculitides. Arthritis Rheum. 37: 18–192, 1994.
47. Jennette, J.C., et al: Nomenclature of systemic vasculitides. Arthritis Rheum. 1995: 9–21, 1996.
48. Guillevin, L., et al.: Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine 75: 17–28, 1996.
49. Luqmani, R.A., et al.: Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. Q. J. Med. 87: 671–678, 1994.
50. Luqmani, R.A., et al.: Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. Q. J. Med. (Churg-Strauss) 78: 352–356, 1989.
51. Tunc, R., et al.: A reaasessment of the International Study Group criteria for the diagnosis (classification) of Behcet’s disease. Clin. Exp. Rheumatol. 19 (Suppl 24): S45–47, 2001.
52. Tunc, R., et al.: A reaasessment of the International Study Group criteria for the diagnosis (classification) of Behcet’s disease. (l). Medical Postgrad. 37: 182–190, 1999.
53. Tunc, R., et al.: A reaasessment of the International Study Group criteria for the diagnosis (classification) of Behcet’s disease. (l). Medical Postgrad. 25: 457–462, 2001.
54. Tunc, R., et al.: A reaasessment of the International Study Group criteria for the diagnosis (classification) of Behcet’s disease. (l). Medical Postgrad. 43: 329–334, 1988.
55. Wolfe, M. M., et al.: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 340: 1888–1899, 1999.
56. Wolfe, M. M., et al.: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 31: 96–111, 1991.
57. Wolfe, M. M., et al.: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. (Evidence) EBM, 2003.
58. J.Q., Huang, et al., Role of Helicobacter pylori and non-steroidal anti-inlammatory drugs in peptic ulcer disease: A meta-analysis, Lancet, (2002), 359, 14-22
59. Bjarnason, I., et al.: Side effects of non-steroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 104: 1832–1847, 1993.
60. Bjarnason, I., et al.: Side effects of non-steroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 35: 1135–1145, 2000.
61. H.O., Conn, T., Poynard, Corticosteroids and peptic ulcer: Meta-analysis of adverse events during steroid therapy, J. Intern. Med., (1994), 236, 619-632
62. H.O., Conn, T., Poynard, Corticosteroids and peptic ulcer: Meta-analysis of adverse events during steroid therapy, Gastroenterol. Endosc., (1990), 32, 1887-1891
63. Remine, S.G., McLlath, D.C.: Bowel perforation in steroid-treated patients. Ann. Surg. 192: 581–586, 1980.
64. Heimdal, K., et al.: High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J. Neurooncol. 12: 141–144, 1992.
65. Fadul, C.E., et al.: Perforation of the gastrointestinal tract patients receiving steroids for neurologic disease. Neurology 38: 348–352, 1988.
66. Edward, L.A.: Corticosteroid-associated perforation of colonic diverticula. Arch. Intern. Med. 150: 1337–1338, 1990.
67. Tyau, E.S., et al.: Acute diverticulitis. A complicated problem in the immunocompromised patient. Arch. Surg. 126: 855–859, 1991.
68. Lanza, F. L., et al.: Endoscopic comparison of esophageal and gastroduodenal effects of risedoronate and alendronate in postmenopausal women. Gastroenterology 119: 631–638, 2000.
69. D.C., Bauer, et al., Upper gastrointestinal tract safety profile of alendronate: The fracture intervention trial, Arch. Intern. Med., (2000), 160, 517-525
70. Schnitzer, T., et al.: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging 12: 1–12, 2000.
71. Ohashi, N., et al.: Cytomegalovirus colitis following immunosuppressive therapy for lupus peritonitis and lupus nephritis. Internal Med. 42: 362–366, 2003.
72. Goodgame, R. W.: Gastrointestinal cytomegalovirus disease. Ann. Intern. Med. 119: 924–935, 1993.
73. Goodgame, R. W.: Gastrointestinal cytomegalovirus disease. Ann. Intern. Med. 28: 196–198, 2002.